Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-Derived Interference in Serum Protein Electrophoresis and Immunofixation Electrophoresis
Author:
Affiliation:
1. Department of Pathology, Duke University Medical Center , Durham NC , USA
2. Department of Pathology, University of Pittsburgh Medical Center , Pittsburgh PA , USA
3. Department of Pharmacy, Duke University Medical Center , Durham NC , USA
Abstract
Publisher
Oxford University Press (OUP)
Subject
General Medicine
Link
https://academic.oup.com/jalm/article-pdf/7/6/1379/46684918/jfac064.pdf
Reference20 articles.
1. Interference of therapeutic monoclonal antibodies with routine serum protein electrophoresis and immunofixation in patients with myeloma: frequency and duration of detection of daratumumab and elotuzumab;Tang;Am J Clin Pathol,2018
2. Expression of daratumumab and elotuzumab migration by capillary electrophoresis relative to transferrin improves precision of their identification;Huls;J Appl Lab Med,2020
3. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 (casirivimab plus imdevimab);U.S. Food and Drug Administration
4. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 (bamlanivimab plus etesevimab);U.S. Food and Drug Administration
5. Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19 (sotrovimab);U.S. Food and Drug Administration
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab;Clinical Biochemistry;2024-05
2. Tixagevimab Plus Cilgavimab Does Not Affect the Interpretation of Electrophoretic and Free Light Chain Assays;American Journal of Clinical Pathology;2022-12-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3